Related references
Note: Only part of the references are listed.Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study
H. Q. Huang et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2007)
Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer
GD Leonard et al.
BMC CANCER (2005)
Psychometric evaluation of two scales assessing functional status and peripheral neuropathy associated with chemotherapy for ovarian cancer: A gynecologic oncology group study
L Almadrones et al.
ONCOLOGY NURSING FORUM (2004)
Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions:: A retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer
L Gamelin et al.
CLINICAL CANCER RESEARCH (2004)
Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy
EA Calhoun et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2003)
Protection against oxaliplatin acute neurosensory toxicity by venlafaxine
JP Durand et al.
ANTI-CANCER DRUGS (2003)
Neurotoxic complications of chemotherapy in patients with cancer - Clinical signs and optimal management
CCP Verstappen et al.
DRUGS (2003)
Clinical aspects and molecular basis of oxaliplatin neurotoxicity: Current management and development of preventive measures
E Gamelin et al.
SEMINARS IN ONCOLOGY (2002)
Chemotherapy-induced peripheral neuropathy
S Quasthoff et al.
JOURNAL OF NEUROLOGY (2002)
Grading of chemotherapy-induced peripheral neuropathy
TJ Postma et al.
ANNALS OF ONCOLOGY (2000)
Share Paper
